Declarations of interest

Updated November 2026.

Pharmaceutical industry. Idorsia Pharmaceuticals, maker of daridorexant: paid speaker, consultancy and advisory work, July 2023 to September 2026. Flynn Pharma, which markets melatonin (Slenyto) in the UK: one paid, sponsored educational talk on children’s insomnia on 1 July 2025, and no other work.

No further paid work from pharmaceutical companies since September 2026. Industry payments to named UK health professionals are published on Disclosure UK.

Commercial. Paid medical advisor to Hypnos Lab, a sleep health company, since July 2026. I co-developed a CBT-I training course for health professionals that is run by The Better Sleep Clinic.

Clinical. NHS general practice in Cambridge. Private practice in sleep medicine at The Better Sleep Clinic.

Charity. Trustee of The Sleep Charity (unpaid) since July 2026; previously a Medical Advisor. The charity had no role in the UK Sleep Prescribing Monitor.

Independence. No company has had any role in my writing or research, including the Monitor. I hold no shares in pharmaceutical, sleep-technology or diagnostics companies.

Relevant interests are declared in full on every publication, conference presentation and application to which they apply.

Note. I was quoted on daridorexant in The Times in May 2026. The article did not carry my declaration of paid work for Idorsia, which I record here.